The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
作者信息
Olson Daniel J, Luke Jason J
机构信息
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637, USA.
出版信息
Immunotherapy. 2019 Feb;11(3):155-159. doi: 10.2217/imt-2018-0171.
Abstract
摘要
相似文献
1
The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.作为免疫治疗药物开发范例的T细胞炎症性肿瘤微环境
Immunotherapy. 2019 Feb;11(3):155-159. doi: 10.2217/imt-2018-0171.
2
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.基于对 T 细胞炎症型与非 T 细胞炎症型肿瘤微环境的理解的癌症免疫疗法靶点。
Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2.
3
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.在T细胞炎症性和非T细胞炎症性肿瘤微环境背景下的肿瘤逃逸机制。
Int Immunol. 2016 Aug;28(8):383-91. doi: 10.1093/intimm/dxw014. Epub 2016 Mar 17.
4
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.T 细胞炎症型与非 T 细胞炎症型肿瘤：癌症免疫治疗药物开发和联合治疗选择的概念框架。
Cancer Immunol Res. 2018 Sep;6(9):990-1000. doi: 10.1158/2326-6066.CIR-18-0277.
5
Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.用于癌症免疫治疗的检查点抑制剂。癌症免疫治疗漫长道路上的多个检查点。
Immunol Cell Biol. 2015 Apr;93(4):323-5. doi: 10.1038/icb.2015.12. Epub 2015 Feb 17.
6
Targeting galectins in T cell-based immunotherapy within tumor microenvironment.在肿瘤微环境中基于T细胞的免疫疗法中靶向半乳糖凝集素
Life Sci. 2021 Jul 15;277:119426. doi: 10.1016/j.lfs.2021.119426. Epub 2021 Mar 27.
7
CCL21 Programs Immune Activity in Tumor Microenvironment.CCL21 调控肿瘤微环境中的免疫活性。
Adv Exp Med Biol. 2020;1231:67-78. doi: 10.1007/978-3-030-36667-4_7.
8
Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.儿科实体瘤的免疫治疗：处于十字路口的治疗方法，重点是抗体。
Cancer Immunol Res. 2020 Feb;8(2):161-166. doi: 10.1158/2326-6066.CIR-19-0692.
9
Mechanisms of immune escape in the cancer immune cycle.癌症免疫周期中的免疫逃逸机制。
Int Immunopharmacol. 2020 Sep;86:106700. doi: 10.1016/j.intimp.2020.106700. Epub 2020 Jun 23.
10
The Reciprocity between Radiotherapy and Cancer Immunotherapy.放疗与癌症免疫治疗的相互作用。
Clin Cancer Res. 2019 Mar 15;25(6):1709-1717. doi: 10.1158/1078-0432.CCR-18-2581. Epub 2018 Nov 9.
引用本文的文献
1
Myeloid Maturity: ATRA to Enhance Anti-PD-1?髓系成熟：ATRA 增强抗 PD-1？
Clin Cancer Res. 2023 Apr 3;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652.
2
The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses.源自T细胞炎症特征的顿悟：CD8A作为跨越临床相关性、癌症预后、免疫抑制环境和治疗反应的生物标志物的泛癌特征。
Front Genet. 2022 Aug 11;13:974416. doi: 10.3389/fgene.2022.974416. eCollection 2022.
3
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.帕博西尼PALOMA-2/3试验的生物标志物对比分析
NPJ Precis Oncol. 2022 Aug 16;6(1):56. doi: 10.1038/s41698-022-00297-1.
4
Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.癌症-免疫循环与治疗干预——纳入患癌宠物犬的机会
Front Oncol. 2021 Nov 19;11:773420. doi: 10.3389/fonc.2021.773420. eCollection 2021.
5
Immune Aging and Immunotherapy in Cancer.免疫衰老与癌症的免疫治疗。
Int J Mol Sci. 2021 Jun 29;22(13):7016. doi: 10.3390/ijms22137016.
6
CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.与CARD相关的风险评分反映免疫格局并预测IDH野生型胶质瘤对抗PD-1治疗的反应性。
Front Cell Dev Biol. 2021 Mar 19;9:653240. doi: 10.3389/fcell.2021.653240. eCollection 2021.
7
Toll-Like Receptor 9 Agonists in Cancer.癌症中的Toll样受体9激动剂
Onco Targets Ther. 2020 Oct 9;13:10039-10060. doi: 10.2147/OTT.S247050. eCollection 2020.
8
WNT Signaling in Melanoma.WNT 信号通路在黑色素瘤中的作用
Int J Mol Sci. 2020 Jul 9;21(14):4852. doi: 10.3390/ijms21144852.
9
Immunogenic cell death in colon cancer prevention and therapy.免疫原性细胞死亡在结直肠癌预防和治疗中的作用。
Mol Carcinog. 2020 Jul;59(7):783-793. doi: 10.1002/mc.23183. Epub 2020 Mar 25.
10
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.WNT/β-连环蛋白信号通路调节肿瘤微环境中的 T 细胞炎症。
Front Immunol. 2019 Sep 26;10:2293. doi: 10.3389/fimmu.2019.02293. eCollection 2019.
本文引用的文献
1
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.SD-101 联合 Pembrolizumab 治疗晚期黑色素瘤的 Ib 期、多中心研究结果。
Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28.
2
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.帕博利珠单抗联合多部位立体定向体部放疗治疗晚期实体瘤患者的安全性和临床疗效。
J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.
3
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.溶瘤病毒疗法可促进肿瘤内T细胞浸润并改善抗PD-1免疫疗法。
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
4
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.干扰素-γ相关的mRNA谱可预测对PD-1阻断的临床反应。
J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.
5
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
6
Radiotherapy and immunotherapy: a beneficial liaison?放疗与免疫治疗：有益的联合？
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379. doi: 10.1038/nrclinonc.2016.211. Epub 2017 Jan 17.
7
The host STING pathway at the interface of cancer and immunity.癌症与免疫界面处的宿主STING通路。
J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892.
8
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
9
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.在黑色素瘤肿瘤微环境中，PD-L1、IDO 和 T（regs）的上调是由 CD8(+) T 细胞驱动的。
Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504.
10
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.MAGE-A3 抗原特异性癌症免疫治疗中的预测基因特征。
J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.
Zotero 插件